Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07691840 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intrathecal Therapy Versus Standard Care for Severe Cancer Pain

Study acronym: CAREGIVER
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Approximately 66% of patients with advanced cancer experience pain, which is often inadequately controlled and associated with a decline in health-related quality of life (HRQoL). Conventional pharmacologic management, ranging from simple analgesics to strong opioids, is frequently limited by insufficient efficacy and systemic side effects. Intrathecal drug delivery (IDD) offers targeted, continuous medication infusion directly into the intrathecal space, allowing lower systemic doses and potentially reducing side effects while maintaining effective analgesia. The CAREGIVER study is a randomized, controlled trial designed to evaluate whether patients with severe refractory cancer pain receiving IDD experience a difference in HRQoL compared to those receiving conventional medical management (CMM) with oral pain medications.
Trial Details
NCT Number NCT07691840
Lead Sponsor Universitair Ziekenhuis Brussel
Conditions
(from sponsor)		 Intrathecal Drug Delivery, Refractory Cancer Pain, Conventional Medical Management
Related terms Cancer Pain
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov